目的 探討培美曲塞聯(lián)合奧沙利鉑作為二線化療方案對(duì)復(fù)發(fā)性卵巢癌患者的療效及臨床安全性。方法 將2011年5月至2012年4月天津醫(yī)科大學(xué)附屬腫瘤醫(yī)院收治的49例復(fù)發(fā)性卵巢癌患者隨機(jī)分為觀察組和對(duì)照組，觀察組23例患者第1天iv培美曲塞500 mg/m2，iv奧沙利鉑135 mg/m2，3周為一療程；對(duì)照組26例患者第1、8天iv吉西他濱1 000 mg/m2，第2天iv奧沙利鉑135 mg/m2，3周為一療程。所有患者均接受4個(gè)以上療程，每2個(gè)療程評(píng)價(jià)療效及不良反應(yīng)。結(jié)果 兩組有效率差異無(wú)顯著性（P＞0.05），但觀察組的不良反應(yīng)明顯減輕（P＜0.05），患者可以耐受。結(jié)論 培美曲塞聯(lián)合奧沙利鉑作為二線化療方案治療復(fù)發(fā)性卵巢癌不良反應(yīng)較輕，患者能夠耐受，可以提高患者的生存質(zhì)量，值得臨床進(jìn)一步研究。

Objective To study the clinical efficacy and safety of pemetrexed combined with oxaliplatin as second-line chemotherapy to treat patients with recurrence ovarian cancer (ROC). Methods A total of 49 patients with ROC, who received the treatment from May 2011 to April 2012 in Tianjin Medical University Cancer Institute and Hospital, were definitely divided into observation group (n=23) and control group (n=26). The patients in the observation group were iv administered with pemetrexed (500 mg/m2) and oxaliplatin (135 mg/m2) on day 1, three weeks as a course; The patients in the control group were iv administered with gemeitabine (1 000 mg/m2) on day 1 and day 8, and with oxaliplatin (135 mg/m2) on day 2, three weeks as a course. All patients received four or more treatment courses, the clinical efficacy and adverse events were compared between the two groups after every two courses of treatment. Results There was no significant difference (P > 0.05) between the two groups, but the adverse reactions in the observation group were reduced significantly (P < 0.05), and the patients could tolerate. Conclusion Pemetrexed combined with oxaliplatin, as second-line chemotherapy, is an effective treatment program with less adverse reactions and the patients could tolerate. At the same time, this program could improve the life quality of patients, which is worthy of further study in clinic.